Real Talk Capital’s Bristol-Myers Squibb BMY Stock Holding History

Real Talk Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$200K	Buy	+3,476	New	+$200K	0.15%	103

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Real Talk Capital's BMY Position: Q2 2026 in Review

Real Talk Capital opened a new position in Bristol-Myers Squibb (BMY) in Q2 2026: 3,476 shares worth $200K. The stake represents 0.15% of the portfolio and ranks #103 among its holdings.

2,508 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Real Talk Capital held 3,476 shares of Bristol-Myers Squibb worth $200K as of Q2 2026.
Bristol-Myers Squibb was a new Real Talk Capital position in Q2 2026.
Bristol-Myers Squibb made up 0.15% of Real Talk Capital's portfolio in Q2 2026, its #103 holding.
2,508 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Real Talk Capital's 13F filing for Q2 2026, filed 14 Aug 2026.